QGEN
NYSE HealthcareQiagen N.V. Common Shares
Diagnostics & Research
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
๐ Market Data
| Price | $34.25 |
|---|---|
| Volume | 1,046,953 |
| Market Cap | 7.06B |
| Dividend Yield % | 0.77% |
| Beta | 0.790 |
| RSI (14-Day) | 15.3 Oversold |
| 200-Day MA | $46.23 |
| 50-Day MA | $41.64 |
| 52-Week High | $57.82 |
| 52-Week Low | $33.17 |
| P/E Ratio | 16.79 |
| Forward P/E | 12.77 |
| Price / Book | 1.87 |
๐ฏ Investment Strategy Scores
QGEN scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (97/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (56/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find QGEN in your text
Paste any article, transcript, or post โ the tool will extract QGEN and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.